Lukas Utiger, currently COO Lonza Life Science Ingredients, will become the new COO of Lonza Bioscience, located in Walkersville, Maryland, USA. He will replace Anja Fiedler who resigned due to personal health reasons. We wish Lukas a successful transition to his new responsibilities and his new location.
Stefan Borgas, CEO, will take over the leadership of the Life Science Ingredients business in addition to his current responsibilities for the next few months until a successor will be named.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.